Abstract Childhood acute myeloid leukemia (AML) represents about 20 % of acute childhood leukemias. Today, the 5-year overall survival rates are close to 70 %. The outcome of childhood AML has significantly improved in the last few decades, secondary to: a better understanding of etiology and risk factors; identification of prognostic factors and their incorporation in treatment protocols; the development of novel therapeutic agents based on cytogenetic and molecular information; implementation of supportive care using evidence-based medicine; and an emphasis on the importance of close follow-up and management of late effects. Further advances in AML management can only occur through continued efforts to understand the disease, and the design of international clinical trials with larger patient groups where novel therapies and treatment protocols can be evaluated.
Introduction
The myeloid leukemias of childhood represent a spectrum of hematopoietic malignancies. More than 90 % of myeloid leukemias are acute and the remainder includes chronic and/or subacute myeloproliferative disorders such as chronic myelogenous leukemia (CML) and juvenile myelomonocytic leukemia (JMML). Myelodysplastic syndromes (MDS) represent less than 5 % of myeloid malignancies in children.
Childhood acute myeloid leukemia (AML) is a very heterogeneous disease that represents only 15-20 % of all childhood leukemia, but unfortunately is still responsible for more than half of the deaths from leukemia. The incidence is 7 cases per million children younger than 19 years of age [1] . There is broad overlap between the recommendations for AML management in children and adults, but, early on in the history of treating childhood AML, it was recognized that guidelines and management should be age-specific, and pediatric protocols were essential. Advances in cytogenetics, molecular biology, and now genomics (a number of novel driver mutations in AML have been identified through whole-genome sequencing) are all adding to a better understanding of AML. The aim of this review is to summarize the current knowledge on childhood AML and our strategies to improve the outcome of this leukemia.
Etiology
AML develops through a transformation of hematopoietic progenitor cells that leads to an arrest in differentiation, overgrowth of a malignant clone in the bone marrow, and a decrease in the number of mature, well-functioning blood cells [2] . Several lines of evidence have led to a model that suggests that AML arises from the cooperation between two classes of genetic alterations that regulate self-renewal and differentiation [2] . Greaves et al. [3] explained the development of childhood AML with a two-step model: leukemia is initiated through chromosomal rearrangements in utero, and the emergence of overt disease is a result of secondary genetic changes.
Risk Factors
Many studies have aimed at determining the risk factors for childhood AML, but evidence is unfortunately still limited, mostly due to small sample sizes, and studies grouping AML with ALL. One way to categorize the possible associations between risk factors and childhood AML is based on the strength of the relationship that was found in different studies and meta-analyses [4 • ].
Generally Accepted Risk Factors
The most common genetic factor is trisomy 21; children with Down syndrome are at an increased risk of leukemia, and nearly half of these cases are usually a specific subtype of AML, acute megakaryocytic leukemia (M7) [5 • ]. Other genetic syndromes associated with childhood AML include Fanconi's anemia, Bloom syndrome, Ataxia telangiectasia, Shwachman-Diamond syndrome, and Monosomy 7.
Ionizing radiation in utero is a well-recognized cause of childhood leukemia, including AML [6] , and this finding has led to decreased X-ray use in pregnant women.
Suggestive of Increased Risk
Parental age has been in the focus of multiple studies looking at risk factors for childhood AML. Data support an increased risk with older maternal age [7] , but are inconclusive for older paternal age. There is some evidence of increased risk with increasing birth order, but this could be secondary to maternal age effect [8] . Some studies also suggest a relationship between prior fetal loss and childhood AML [9] . Birth weight is determined by a combination of genetic and in utero factors. Two independent metaanalyses have suggested that there may be an increased risk with both low and high birth weight [10] .
Periconceptional and prenatal exposure may also be associated with an increased risk of childhood AML. There appears to be a positive correlation with alcohol consumption during pregnancy [11] , but not with tobacco. Another meta-analysis showed a positive correlation between maternal occupational pesticide exposure and childhood AML; studies for paternal exposure were more heterogeneous [12] .
Suggestive of Decreased Risk
Breastfeeding is the only factor that has a protective effect on the development of childhood AML; multiple studies found a decreased risk for AML in children who were breastfed for more than 6 months [13] .
Limited Evidence
Most of the data on periconceptional and prenatal exposures indicate non-significant but positive relationships with childhood AML. The most important factors are parental benzene exposure [14] , parental smoking [15] , antibiotic use during pregnancy [16] , and maternal dietary consumption of DNA topoisomerase II inhibitors (e.g., bean, soy, cocoa, coffee, wine, canned vegetables) [17] .
Prognostic Factors
In the past, the prognosis for children with AML was only determined by a few limited host and disease factors including morphology, white blood cell count at the time of diagnosis, age, or response to induction therapy. Recent advances in technology have helped to identify molecular and cytogenetic risk factors in AML which provide insight into the molecular heterogeneity of the disease and can explain the previously observed differences in therapeutic response [18] .
Classification of AML
Two systems have been used to classify AML into subtypes: the French-American-British (FAB) classification and the newer World Health Organization (WHO) classification.
1. The FAB classification of AML is based on the morphologic and cytochemical features of leukemic blasts in the bone marrow. Subtypes M0 through M5 all start in precursors of white blood cells. M6 AML starts in very early forms of red blood cells, while M7 AML starts in platelet precursors ( Fig. 1 ; Table 1 ) [19] . Despite the extremely heterogeneous nature of AML, the various subtypes seem to share some common pathways leading to leukemogenesis, and the hierarchical nature of the disease is generally well established. at genetic, epigenetic, proteomic, and immunophenotypic classification, AML classification will likely evolve further.
Host Factors
The factors having an impact on disease outcome are the following: age, gender, race, BMI, and host polymorphism. Recent studies have demonstrated that young patients with AML have better survival rates because of lower relapse rates [23] . Racial differences have been recently shown to be an important prognostic factor, as African Americans were found to have a significantly worse outcome secondary to a higher rate of relapse [24] . The explanation is thought to be due to polymorphisms in genes involved in drug metabolism and DNA repair (e.g., glutathione S-transferase) [25] . Retrospective analysis of data has found an association between children being overweight ([94th percentile) or underweight (\11th percentile) and early treatment-related mortality, mostly from infection [26] .
Response to Therapy
Response to induction therapy has been a major prognostic factor since the beginning of risk stratification. The amount of blasts remaining in the bone marrow after the first course of induction therapy divide patients into three groups: complete remission with blasts less than 5 %, in partial remission patients have blasts between 5 and 15 %, and with resistant disease they have more than 15 % blasts in the bone marrow. The impact of therapy response upon survival has been clearly demonstrated [27] . Patients in partial remission after the first course of induction had better overall survival rates than patients with resistant disease (42 and 22 %, respectively). Patients in partial remission after the first induction course had a high remission rate (89 %) after the second induction course and had an overall survival rate only slightly inferior to the group with complete remission after the first course of treatment. Patients with resistant disease had a poor prognosis even if they entered remission after the second course of induction therapy.
Response to therapy used to be determined by morphologic exam of the bone marrow. More recent methods are based on multiparameter flow cytometry and polymerase chain reaction (PCR). These methods made possible the introduction of minimal residual disease (MRD), which quickly became one of the main prognostic factors in response to therapy. Patients who were MRD-positive after the first course of induction fared significantly worse than patients with no MRD [28] . MRD also has an impact on the success of stem cell transplant (SCT). Patients who were MRD-negative after SCT had a significantly lower relapse rate than patients with MRD [29] .
Cytogenetics
Cytogenetics in AML is one of the most important prognostic factors in all age groups. Based on cytogenetics alone, patients can be placed in three major risk groups impacting relapse risk, disease-free survival, and overall survival (Table 2) .
Briefly, favorable AML cytogenetics are the following: core binding factor leukemias t(8;21), and inv(16), t(15;17). Core binding factors play a crucial rule in the different stages of hematopoiesis. They are heterodimeric transcription factors containing a DNA-binding alpha subunit and a beta subunit, which increases the affinity and stabilizes the binding of the alpha subunit. Translocation (8;21) disrupts the AML1 gene, which is coding the alpha subunit, whereas inv(16) creates two different fusion genes, which affects the quantity of the beta subunit [30, 31] . Translocation (15;17) fuses the retinoic acid receptor-a gene to the PML gene and it occurs only in acute promyelocytic leukemia (APL). The product of the RARA gene is a nuclear receptor that acts as a transcription enhancer in response to retinoic acid [32] .
Unfavorable cytogenetics include complex cytogenetics (three or more distinct cytogenetic abnormalities), monosomy 7, monosomy 5, del(5q), and abnormal chromosome 3. Chromosomes 5q and 7 contain tumor suppressor genes that regulate myeloid growth and differentiation [33, 34] . The 5q-syndrome is characterized by treatment-resistant macrocytic anemia, and MDS that may lead to AML [34] .
Intermediate risk cytogenetics refer to all the remaining chromosomal abnormalities, like ?8, ?21, or 11q23 (MLL)-associated abnormalities. The most common genetic events occurring in children younger than 1 year are the rearrangements of the mixed lineage leukemia (MLL) gene on chromosome 11 [35] , and the frequency decreases with age [36] . It plays a key role in hematopoiesis by regulating the 
Molecular Risk Factors
Genomic alterations of several genes involved in AML development have been recently discovered and linked to the outcome of the leukemia. There are three mutations, which have been already proven to significantly influence the course of the disease. FLT3 is a receptor tyrosine kinase, and its mutation has been associated with higher risk of relapse [38] . Nucleophosmin 1 encodes a nuclear protein, and one of its main tasks is the regulation of centrosome duplication. Patients with NPM1 mutation showed improved survival [39] . CCAAT/enhancer-binding protein alpha (CEBPA) gene is encoding a transcription factor, which plays a crucial role in granulopoiesis, and loss of its activity results in a block of normal differentiation. Patients with CEBPA mutation showed longer eventfree survival and decreased incidence of relapse [40] .
Researchers examined other well-known mutations associated with different malignancies, such as WT-1 or c-KIT mutations, but they did not demonstrate a significant impact on the prognosis. Children with Down syndrome represent a special patient group. The first genetic event in leukemogenesis is considered to be trisomy 21, while the second genetic event is a mutation of the X-linked GATA1 gene, which is an important blood-specific transcription factor in the development of the erythroid and megakaryocytic lineages. Molecular studies of newborn blood samples suggest that the GATA1 mutation occurs in utero, while the genetic abnormalities (e.g., mutations in JAK3, p53, FLT3 genes) playing a crucial part in the evolution of acute megakaryoblastic leukemia usually happen in early childhood [5 • ].
In the last 10-15 years, these prognostic factors have been incorporated into therapeutic decision-making, allowing us to reduce toxicity for those who can be cured with less intensity, to develop target therapy to specific types of AML, and most importantly to improve the overall survival and event free survival rates [41 • ].
Clinical Features and Diagnosis
The signs and symptoms of AML are mainly due to the replacement of bone marrow with malignant cells. Bone marrow failure presents as pallor, fatigue, exercise intolerance, bruising or epistaxis, and fever caused by different infections. Organ infiltration can cause hepatosplenomegaly, gingival hyperplasia (M4, M5 subtypes), or, especially in children less than 1 year of age, central nervous system involvement and subcutaneous nodules or ''blueberry muffin'' lesions. Laboratory findings of disseminated intravascular coagulation (DIC) are indicative of APL (M3 subtype). A myeloid sarcoma or chloroma is a solid tumor composed of myeloblasts, typically associated with a t(8;21) translocation in the M2 subtype, and the most common sites are epidural sites, mediastinum, lungs, and the orbit of the eye. The basic diagnostic work-up for childhood AML consists of relevant blood tests, bone marrow aspiration and biopsy (flow cytometry, special stains, cytogenetics, FISH, RT-PCR), chest x-ray and lumbar puncture.
Histochemical Evaluation
The treatment for children with AML differs significantly from that for ALL; thus, it is crucial to distinguish AML from ALL. Special histochemical stains performed on bone marrow specimens of children with acute leukemia can be helpful in confirming diagnosis. The stains most commonly used include myeloperoxidase, periodic acid-Schiff (PAS), Sudan Black B, and esterase. In most cases, the staining pattern with these histochemical stains will distinguish AML from AMML and ALL. This approach, which in most developing countries is the only means of making a diagnosis, is slowly being replaced by immunophenotyping using flow cytometry.
Immunophenotyping
The use of monoclonal antibodies to determine cell-surface antigens of AML cells is used to reinforce histologic diagnosis. Various lineage-specific monoclonal antibodies that detect antigens on AML cells should be used at the time of initial diagnostic work-up, along with a number of lineage-specific T-lymphocyte and B-lymphocyte markers to help distinguish AML from ALL and bi-lineal or biphenotypic leukemia [42] . The expression of various CD proteins that are relatively lineage-specific for AML include CD33, CD13, CD14, CDw41 (or platelet antiglycoprotein IIb/IIIa), CD15, CD11B, CD36, and antiglycophorin A.
Treatment
Initially, the general management of childhood AML was adapted from treatment protocols developed to treat adult AML. Over the last 50 years, advances in biological research and the ability to perform large clinical trials in children have made it possible to increase cure rates and improve the quality of life of the long-term childhood AML survivors.
Conventional Chemotherapy
One of the major advances in the last couple of decades has been the introduction of aggressive induction therapy. One or two courses of induction therapy are regularly used, and the standard induction therapy contains 3 days of anthracycline (daunorubicin, idarubicin, or mitoxantrone) and 7-10 days of cytarabine. Several international studies have already proven that the induction regimen comprising of higher doses of anthracyclines has improved long-term survival rates [43] . One of the feared side effects of anthracyclines is acute or late cardiotoxicity, which limits the cumulative dose. To prevent toxicity and further increase the cumulative dose, a liposomal formulation of daunorubicin was developed, which has had promising results according to the AML-BFM 2004 trial [44] .
Cytarabine (Ara-C) is one of the most active agents in AML, and the most important in consolidating and maintaining remission. Studies on standard dose versus high dose, and intensively timed cycles versus standard timing of treatment have shown that high dose Ara-C-based intensification regimens can significantly reduce relapse rates [45] . On the other hand, ongoing maintenance therapy after aggressive intensification therapy led to worse survival rates post-relapse, most likely due to increased drug resistance [46] .
Stem Cell Transplantation (SCT)
Stem cell transplantation, using myeloablative chemotherapy rather than whole body radiation, can be part of the postremission consolidation therapy. Risk stratification plays an important role in deciding which patient gets the most benefit, including the graft-versus-leukemia effect, with allogeneic SCT. There is consensus that SCT should be offered to patients with high-risk or refractory AML, and to all children with relapsed AML in second complete remission [47] . According to the latest guidelines, MRD is monitored routinely, especially because high levels of MRD prior to SCT have been associated with poorer outcome [48] .
New Agents
One of the main reasons behind improvement in survival rates in the last three decades was intensification of the conventional cytotoxic chemotherapies. But they have reached their limits, which has led to the realization that less toxic and more effective therapies are needed. Recent advances in technology have helped us identify molecular and cytogenetic alterations, and novel therapies now specifically target these leukemogenic abnormalities. Several early-phase clinical trials have been already completed with promising results [49 • ].
The purine nucleoside analog cytarabine has long been the backbone of the conventional AML therapy. Its novel derivative, clofarabine, was designed to have increased efficacy, both via impairing DNA-synthesis and repair and by inducing apoptosis via mitochondrial pathways [50] . It has been trialed as a single agent, in combination with liposomal daunorubicin, and with targeted therapeutic agents showing encouraging results [51] [52] [53] .
Internal tandem duplication (ITD) of the fms-like tyrosine kinase 3 (FLT3) gene is a frequent molecular aberration in childhood AML and it increases with age. It results in a constitutive FLT3 signaling, which stimulates proliferation. First-generation FLT3 inhibitors (lestaurtinib and midostaurin) are non-selective compounds, while secondgeneration inhibitors like quizartinib have selectivity and increased potency for FLT3 [54] . All these agents are already in clinical trials in different stages of development. The best results are being achieved when they are used in combination with conventional chemotherapy. Sorafenib is a multi-kinase inhibitor, and has a strong activity against FLT3. It has been tested in combination with cytarabine, with clofarabine in relapsed/refractory AML [53] , and with HSCT after the first remission in children with FTL3-ITD ? AML [38] .
Immunotherapy
Immunotherapy in AML is represented by the calicheamicin-conjugated CD33 antibody, gemtuzumab ozogamicin. The drug was used as monotherapy in relapsed/ refractory AML, or it was combined with chemotherapy or HSCT, which resulted in the reduction of MRD [55] . Unfortunately, in 2010, the FDA withdrew marketing approval based on lack of benefit in relapsed AML, and increased induction mortality in adults. In spite of the confirmed survival benefit when added to the induction therapy regimen [56] , it most likely will be difficult to use in children outside of clinical trials.
There are multiple promising agents, which have been already tested in adult studies, waiting to be included in pediatric trials, including aurora kinase inhibitors, aminopeptidase inhibitors, c-KIT inhibitors, epigenetic therapies, and MEK inhibitors [47] .
Special Patient Groups
Acute Promyelocytic Leukemia (APL) Acute promyelocytic leukemia represents a special patient group. It is characterized by the chromosomal rearrangement t(15;17)(q22;q21), which results in a product containing the retinoic acid receptor-a, which responds to ATRA. APL is a medical emergency because of the risk of hemorrhage secondary to DIC, so treatment needs to be initiated immediately. Standard care consists of an induction therapy with ATRA and anthracycline therapy, followed by an anthracycline-based consolidation therapy. One of the side effects of ATRA, especially with high WBC count, is APL differentiation syndrome with signs and symptoms of fever, weight gain, respiratory distress, and pleural and pericardial effusions. The combined use of ATRA and chemotherapy has helped to decrease the incidence of this feared adverse effect [57] . Maintenance therapy with ATRA using an intermittent dosing schedule has proven to be beneficial in this subtype of AML. Arsenic trioxide (ATO) is a promising agent in the management of relapsed APL [58] , and has recently also been used in trials in newly diagnosed patients [59] . A possible synergistic effect was found when ATO and ATRA were combined, demonstrated by the significant shortening in the time to complete remission and decrease in the fusion transcripts detected by RT-PCR [60] .
Down Syndrome
Another unique patient population is children with AML in Down syndrome and other genetic disorders. In Down syndrome, the leukemic blast originates from fetal liver hematopoiesis, and 5 % of the children have transient leukemia at birth [61] . In their first 4 years of life, 10-20 % of them will develop myeloid leukemia with megakaryoblastic features. The disease has a good prognosis, and intensity-reduced chemotherapy without SCT results in a survival rate over 85 % [62] . Children with congenital syndromes characterized by impaired DNA-repair or disturbed myelopoiesis are at an increased risk developing AML. The backbone of their therapy is less intensive chemotherapy followed by allo-SCT [63] .
Therapy-Related AML/Myelodysplastic Syndromes
The development of AML or MDS following treatment with ionizing radiation or chemotherapy, particularly alkylating agents and topoisomerase inhibitors, is termed therapy-related (t-AML or t-MDS, respectively). The risk of t-AML/t-MDS is regimen-dependent and related to the cumulative doses of chemotherapy agents received, as well as the dose and field of radiation administered [64, 65] . Previously used protocols that employed high cumulative doses of either epipodophyllotoxins (e.g., etoposide or teniposide) or alkylating agents (e.g., mechlorethamine, melphalan, busulfan, and cyclophosphamide) induced excessively high rates of t-AML/t-MDS that in some cases exceeded 10 % [65] . However, most current chemotherapy regimens used to treat childhood cancers have a cumulative incidence of t-AML/t-MDS not greater than 1-2 %. t-AML/t-MDS resulting from epipodophyllotoxins and other topoisomerase II inhibitors (e.g., anthracyclines) usually occur within 2 years of exposure and are commonly associated with chromosome 11q23 abnormalities [66] , although other subtypes of AML (e.g., APL) have been reported [67] . t-AML following exposure to alkylating agents or ionizing radiation often occurs 5-7 years later, and is commonly associated with deletions of chromosomes 5 and 7 or a monosomy [66] .
Future improvements in the treatment of childhood AML will come from better risk-group stratification, development of novel therapeutic agents, and the revision of current protocols based on international multi-center trials. It is expected that high-quality cure can be achieved for most of the children with AML [68] .
Supportive Care
As aggressive induction, post-remission consolidation, and maintenance therapy started improving the outcome in childhood AML, mortality related to treatment significantly increased. There was an urgent need to develop supportive care guidelines, and, since their institution, there has been a decrease in the number of deaths during the induction phase, when patients are the most susceptible to toxic side effects and infections [69] .
1. Hyperleukocytosis is defined as an initial white blood cell count over 100 K/mm 3 , and is considered a hematologic emergency. Patients with life-threatening coagulopathy and leukostasis are best treated with leukapheresis or double-volume exchange transfusion. This controlled cell reduction together with induction chemotherapy, enforced diuresis, and administration of rasburicase (recombinant urate oxidase) can prevent severe tumor lysis syndrome [70 •• , 71] . 2. Acute and late cardiotoxicity is one of the main limiting factors of anthracycline use. Development of a liposomal formulation of daunorubicin allows us to administer higher cumulative doses [44] . Cardioprotection with dexrazoxane was a promising option to reduce toxicity, but it was shown to have a possible relationship with a higher rate of secondary malignancies, so the drug is being used with caution [72] . 3. Increasing intensity of therapy has resulted in longer periods of severe neutropenia (absolute neutrophil count less than 500 cells/mm 3 ). During this time, fever may be the only indication of an underlying infection. The Infectious Disease Society of America updated its practice guidelines for the management of neutropenic fever and provided recommendations on risk stratification, and treatment algorithms [73] . Briefly, (1) risk assessment will decide if the patient needs to be hospitalized for IV antibiotic treatment, or can be managed as an outpatient, and will also determine the length of the treatment; (2) laboratory tests should include complete blood cell count with manual differentiation, complete metabolic panel, blood culture, culture specimens from other sites of suspected infection, and a chest x-ray for patients with respiratory symptoms; (3) the appropriate empiric antibiotic treatment is an anti-pseudomonal b-lactam agent, and addition of vancomycin or linezolid needs to be considered if there is a suspected MRSA or VRE infection; (4) antibiotic regimen should be modified based on microbiological data or with unresolved or new signs and symptoms; (5) duration of treatment is determined by the organism and site, or the duration of the neutropenia; and (6) antifungal therapy has to be considered if the fever is persistent or recurs after 4-7 days of antibiotic treatment. Antibiotic prophylaxis with fluoroquinolone might be considered for high-risk patients with prolonged neutropenia [74] .
The incidence of invasive fungal infection in children
with AML is about 20 % [69] . In adults, prophylactic posaconazole has significantly decreased the incidence of invasive aspergillosis, but unfortunately it is not licensed for children younger than 13 years [75] . Cotrimoxazole prophylaxis is routinely used to prevent Pneumocystis jirovecii infection. 5. Neutropenic enterocolitis or typhlitis is another severe complication induced by chemotherapy. It is characterized by fever, right lower quadrant tenderness, diarrhea, nausea, and emesis; symptoms usually improve once the neutropenia is resolved. It usually affects the ileocecal region confirmed by different radiologic imaging modalities. Optimal management is often supportive, while surgical treatment is rarely indicated [76] . 6. The earlier-mentioned APL differentiation syndrome presents with fever, weight gain, pleural and pericardial effusion, and respiratory distress. Treatment includes intravenous dexamethasone, temporary discontinuation of ATRA, and supportive measures with diuretics, dialysis, or mechanical ventilation. Severe differentiation syndrome is associated with higher frequency of thrombosis, hepatotoxicity, hemorrhage, or death [77] . Pseudotumor cerebri is another wellknown side effect of ATRA, occurring in about 10 % of children, and can be treated with steroids [78] . 7. Red blood cell, platelet, and fresh frozen plasma transfusions are routinely used throughout the chemotherapy courses. Washed, leukocyte-reduced, irradiated, and CMV-negative products are preferred to reduce complications.
Better supportive care strategies played a central role in the improving outcome of childhood AML seen in the last decades. Continuous monitoring and vigilance are crucial to prevent treatment related toxicities and death.
Monitoring Late Effects
Quality of life in long-term survivors of AML is just as important as overall survival rates. The treatment of AML is characterized by higher doses of anthracycline, shorter duration, less frequent use of CNS radiation, and more frequent use of allogeneic SCT. Therapeutic improvements are contributing to a growing number of adolescents and adults, who were successfully treated for childhood AML, but our data are still scarce on the incidence on late sequelae. Frequent follow-up with monitoring for signs and symptoms of relapse and late effects is a vital element in the management of childhood AML (Table 3 ) [79, 80] .
Growth abnormalities are one of the most common late effects, with some requiring growth hormone substitution. CNS radiation often results in short stature and obesity [81] , while total body radiation and SCT cause poor overall growth. Endocrinopathies including hypothyroidism, hypogonadism, and even infertility are another burden of aggressive treatment and radiation. There has been no increase in the incidence of birth defects or cancer in babies born to childhood AML survivors [79] .
Cardiac dysfunction following high-dose anthracycline therapy occurs in less than 10 % of the survivors [79] . Serial ECGs and echocardiograms are necessary for early recognition of cardiomyopathy and heart failure. Less than 15 % of long-term survivors developed benign solid tumors, most of them requiring surgery [79] . Other late effects observed amongst these patients were cataracts, radiation-induced dental abnormalities, restrictive lung disease, and chronic GVHD.
During the intensive chemotherapy phases, almost all patients need blood transfusions. The number of patients becoming seropositive for hepatitis B and hepatitis C has been steadily decreasing over the last decade with the more precise screening techniques used for blood products.
Beside physical late effects, neurocognitive and psychosocial issues also deserve attention in follow-up care. Post-SCT, children may have academic difficulties at school with problems in learning, adjustment, and lower self-esteem.
However, the majority of AML survivors do well and appear to attain levels of education, marriage, and employment comparable to those reported in the general population [80] .
Conclusion
The outcome of childhood AML has significantly improved since the very first treatment protocols were instituted in the early 1950s; however, we still have a long way to go. While overall survival is almost close to 70 %, the prognosis for certain subtypes such as M7 still remains dismal. Every decade has added something new to diagnosis and treatment, resulting in better survival rates. In the 1970s and 1980s, the introduction of anthracyclines and cytarabine was the first step towards meaningful survival, which was followed by the incorporation of allogeneic SCT in the 1990s. Advances in cytogenetics and molecular genetics in the early twenty-first century have resulted in better risk stratification and development of treatment protocols based on these risk factors. Meanwhile, supportive care and longterm follow-up continues to improve.
It is clear that the direction in which we are heading is individualized treatment. The extensive use of genetic mapping, the development of novel therapeutic agents based on the genomic alterations, and international clinical trials providing evidence-based medicine are key factors in the improvement of AML survival rates in children.
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